IMMUNEERING TO ANNOUNCE 12-MONTH OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON JANUARY 7, 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.